Vol 17, No 05, May 2013 - Asia — The Future in Generics & Biosimilars
Quality Issues in Pharmaceuticals
Patient safety and wellness has always been at the forefront of the pharmaceutical industry. The consequence of that is the need to maintain high quality standards for pharmaceutical products. This end-goal has to be maintained despite escalating costs and cuts on funding. As a result, pharmaceutical companies are shifting their operations to Asia and the Middle East in an attempt to alleviate the financial pressures in the West. Here, our authors discuss the effects of the current climate in the pharmaceutical industry and how globalization has made its impact - for better or worse.
Read More >>
Biosimilars: where we stand today?
As the patent cliff takes effect, comes the rise of biosimilars. They are supposedly the replicas of their brand name innovator pharmaceuticals. Biosimilars are typically priced lower than their brand name counterparts. How will biosimilars fair against the reputation surrounding their brand name competitors? Will biosimilars be able to 'steal' the market share away from branded products? Jack Aurora of Hisun Pharmaceuticals writes about the regulatory landscape of this upcoming industry, what its future might entail and success stories to learn from.
Read More >>